Gao Y, Luo XD, Yang XL, Tu D. Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis . World J Clin Cases 2021; 9(30): 9090-9100 [PMID: 34786391 DOI: 10.12998/wjcc.v9.i30.9090]
Corresponding Author of This Article
Dong Tu, MD, Professor, Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China, No. 212 Daguan Road, Xishan District, Kunming 650032, Yunnan Province, China. tudongyisheng@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2021; 9(30): 9090-9100 Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9090
Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis
Yang Gao, Xiao-Di Luo, Xiao-Li Yang, Dong Tu
Yang Gao, Xiao-Di Luo, Xiao-Li Yang, Dong Tu, Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China, Kunming 650032, Yunnan Province, China
Author contributions: Tu D made substantial contributions to the conception and design of the work; Gao Y and Luo XD searched and selected the materials, extracted the data, and wrote this manuscript; Yang XL and Tu D revised the paper carefully and also contributed to the statistical analysis; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Tu, MD, Professor, Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China, No. 212 Daguan Road, Xishan District, Kunming 650032, Yunnan Province, China. tudongyisheng@126.com
Received: March 30, 2021 Peer-review started: April 1, 2021 First decision: June 23, 2021 Revised: June 25, 2021 Accepted: September 2, 2021 Article in press: September 2, 2021 Published online: October 26, 2021 Processing time: 205 Days and 5.4 Hours
ARTICLE HIGHLIGHTS
Research background
The clinical role of breast cancer susceptibility gene 1 (BRCA1) expression in non-small cell lung cancer (NSCLC) patients undergoing surgery remains unclear.
Research motivation
This study explored the clinical value of BRCA1 expression in resected NSCLC patients.
Research objectives
This study aimed to explore the relation of BRCA1 expression with clinicopathological characteristics and survival in patients with resected NSCLC.
Research methods
Several electronic databases were searched to identify the relevant articles. The combined relative risks or hazard ratios with their corresponding 95%CIs were estimated.
Research results
The expression of the BRCA1 was significantly correlated with the prognosis of resected NSCLC. Positive BRCA1 expression signified a shorter overall survival and disease-free survival. However, no significant association of BRCA1 expression with any clinicopathological parameters was observed.
Research conclusions
BRCA1 expression indicated a poor prognosis in resected NSCLC patients. BRCA1 might serve as an independent biomarker to predict clinical outcomes and help to customize optimal adjuvant chemotherapy for NSCLC patients who received surgical therapy.
Research perspectives
BRCA1 could serve as a novel biomarker in resected NSCLC for the evaluation of prognosis and formulation of treatment strategy.
